Saakshi Khattri, MD, discusses how real-world comparative effectiveness data suggest a potential class-level signal for risankizumab and IL-23 inhibition in reducing the risk of psoriatic arthritis among patients with psoriasis.
Risankizumab in Psoriatic Disease: New Evidence on Prevention, Long-Term Efficacy, and Safety
Advertisement
Advertisement
Trending on HCPLive
1
FDA Approves Roflumilast 0.3% Cream for PsO in Children 2-5 Years
2
FDA Issues CRL for Oxylanthanum Carbonate in Hyperphosphatemia for CKD Patients on Dialysis
3
Functional Cures for T1D: Insulin Independence Through Islet Transplantation
4
Hypercortisolism as a Driver of Hypertension and Cardiovascular Risk
5